PlanIt Research, LLC. | Houston, TX

Research site

(Unclaimed)

Location

10837 Katy Freeway Suite 200, Houston, Texas, United States of America

Site insights

Top conditions

Top treatments

Sugar

Tirzepatide

Metformin

LY3841136

LY3298176

Semaglutide

Macupatide

Insulin icodec

LY3305677

LY3549492

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 38 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling

Overweight

Obesity

Drug: LY3532226

Drug: LY3841136

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Active, not recruiting

Obesity

Drug: Semaglutide

Drug: Semaglutide placebo

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 pa...

Active, not recruiting

Obesity

Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

Drug: CagriSema (Cagrilintide B and Semaglutide I)

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with ob...

Enrolling

Overweight

Obesity

Drug: Macupatide

Drug: Macupatide Placebo

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling

Hypothyroidism

Drug: Levothyroxine

Drug: Armour Thyroid

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS)

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10...

Active, not recruiting

Type 2 Diabetes (T2DM)

Metabolic Syndrome (MetS)

Drug: Obicetrapib 10 mg

Other: Placebo

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: LY3841136

Locations recently updated

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and sa...

Enrolling

Overweight

Obesity

Drug: Macupatide

Drug: Eloralintide

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or ob...

Enrolling

Overweight and/or Obesity

Overweight

Drug: PF-08653944

Other: Placebo

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 di...

Enrolling

Overweight

Diabetes Mellitus

Drug: NNC0487-0111

Drug: Placebo (matched to NNC0487-0111)

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ren...

Active, not recruiting

Type 2 Diabetes

Drug: Retatrutide

Drug: Placebo

Locations recently updated

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of car...

Enrolling

Overweight

Atherosclerotic Cardiovascular Disease

Drug: Maridebart Cafraglutide

Drug: Placebo

Locations recently updated

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to...

Enrolling

Overweight

Obesity

Drug: ABBV-295

Drug: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo